Abstract:PI4K2A is a potent potential biomarker for early diagnosis, prognosis, and treatment of COAD. In addition, PI4K2A is an independent prognostic element of COAD and is closely interrelated with immunotherapy. Moreover, many anti‐cancer drug sensitivities were negatively correlated with PI4K2A expression, providing some new ideas for the treatment of COAD. However, our findings need to be further validated by in vivo and in vitro assays. Background PI4K2A has been found to have a tumor‐promoting role in various solid tumors and be involved in various biological procedures. In this article, we aim to investigate the prognostic values of PI4K2A and provide new insights in colon adenocarcinoma (COAD). Methods The Cancer Genome Atlas (TCGA) database, Human Protein Atlas online database, and UALCAN database were used to analyze the expression of PI4K2A in COAD and the survival of patients. Univariate and multifactorial Cox regression analyses were used to assess the prognosis of PI4K2A on COAD. GSEA was used to explore PI4K2A‐related signaling pathways. In addition, the effect of PI4K2A on immune checkpoint inhibitors (ICIs) treatment was investigated by constructing a TIDE model and predicting the association between PI4K2A and anticancer drug sensitivity through the CellMiner database. Results In the TCGA database, PI4K2A was highly expressed in COAD and the similar results were verified by qRT‐PCR. Survival analysis, utilizing Kaplan–Meier curves, revealed that COAD patients with high PI4K2A expression had a worse prognosis. In addition, PI4K2A expression was discovered to have been associated with T‐stage, N‐stage, and pathological stage by logistic analysis. Next, we utilized univariate and multifactorial Cox regression analyses to identify PI4K2A as an independent predictor. Additionally, GSEA analysis indicates that PI4K2A is enriched in MAPK signaling pathway, Toll‐like receptor signaling pathway, etc. In COAD, PI4K2A was remarkably associated with the tumor immune microenvironment. In addition, by constructing a TIDE model, we discovered that COAD patients in the PI4K2A low‐expression cohort were better treated with ICI. Finally, analysis of the CellMiner database predicted that PI4K2A was adversely correlated with the sensitivity of various anticancer drugs. Conclusions Our study suggests that PI4K2A may be a potential predictor of poor prognosis in COAD and a potential biomarker for early diagnosis, prognosis, and treatment.

High expression of PIK3CB is an independent prognostic predictor for gastric adenocarcinoma

Clinicopathological and related gene analysis in gastric adenocarcinoma and their correlation with prognosis

Expression, Characteristics, and Clinical Target Prediction of PIK3C3/ vps34 in Gastric Cancer

Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer

Genetic and bioinformatic analyses of the expression and function of PI3K regulatory subunit PIK3R3 in an Asian patient gastric cancer library

Associations of PIK3CA mutations with clinical features and prognosis in gastric cancer.

Upregulation of PIK3IP1 monitors the anti-cancer activity of PI3Kα inhibitors in gastric cancer cells

High Expression of PIGC Predicts Unfavorable Survival in Hepatocellular Carcinoma

Phosphatidylinositol 3-kinase CB association with preoperative radiotherapy response in rectal adenocarcinoma.

High Expression of PIG11 Correlates with Poor Prognosis in Gastric Cancer

Pan-cancer Analysis of the Prognostic and Immunological Effects of PIK3C3

Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment

PIK3CD correlates with prognosis, epithelial-mesenchymal transition and tumor immune infiltration in breast carcinoma

SP1 Mediated PIK3CB Upregulation Promotes Gastric Carcinogenesis

High expression of PI4K2A predicted poor prognosis of colon adenocarcinoma (COAD) and correlated with immunity

Combined Examination of P27(kip1), P21(waf1/cip1) and P53 Expression Allows Precise Estimation of Prognosis in Patients with Gastric Carcinoma.

Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer.

Polo Like Kinase 1 Expression and Prognostic Value in Gastric Carcinomas

Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment

High Ki67 Expression Has Prognostic Value in Surgically-Resected T3 Gastric Adenocarcinoma

Expression of P21(waf1/cip1) and P53 Proteins in Gastric Carcinoma: Its Relationships with Cell Proliferation Activity and Prognosis.